Product
VLX-1005
2 clinical trials
4 indications
Indication
Heparin-induced ThrombocytopeniaIndication
ThrombocytopeniaIndication
ImmuneIndication
Heparin-Induced ThrombocytopeniaClinical trial
A Phase I, Open-Label, Randomized, Three-Period, Three-Sequence Crossover Study of the Effects of Co-administration of Intravenous VLX-1005 With Argatroban on Pharmacokinetics, Pharmacodynamics and Safety in Healthy Adult SubjectsStatus: Completed, Estimated PCD: 2022-04-01
Clinical trial
A Randomized, Double-Blind, Phase 2 Pilot Study of VLX-1005 Versus Placebo in Participants With Suspected Heparin Induced Thrombocytopenia Treated With Background Standard of CareStatus: Recruiting, Estimated PCD: 2024-12-21